Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies - Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing Meeting Abstract
| Authors: | Hamlin, P. A.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; Kim, Y.; Curnutte, J. T.; Patel, M. R. |
| Abstract Title: | Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies - Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 409s |
| Language: | English |
| ACCESSION: | WOS:000404711505070 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.7557 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7557 -- Source: Wos |
